PVLA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Palvella Therapeutics, Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 139.0 USD
0.7% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 18.4% above the Trend Line and sits at 82.2% of its 52-week range. The latest completed week returned 0.7%, after a -5.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 45/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 67 out of 100
Latest Close 139.0 USD 31 Jul 2026
1W Return 0.7% latest completed week
4W Return -5.3% short-term follow-through
12W Return 14.6% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 56-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 7 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.7% Latest completed week; four-week move -5.3%. Indicator stack 100/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 58.04% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 45/100 conviction; expected move 12.4%. News sentiment 56/100 64 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 18.4% above the Trend Line and sits at 82.2% of its 52-week range. The latest completed week returned 0.7%, after a -5.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6812-week average 0.73

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.68Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers77 reversal markers

No recent accumulation markers. 7 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.3% over four weeks, 14.6% over 12 weeks, and 280.4% over one year. The current trend has remained active for 56 consecutive weeks.

Performance by holding period

1W0.7%
4W-5.3%
12W14.6%
26W81.3%
52W280.4%
Active trend streak56 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.37Latest activity-pressure read.
Pressure change638.8%Four-week change in activity pressure.
Leadership29.55Latest relative-leadership reading.
RS change-30.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength45/100Blend of value, momentum, and quality. Underlying universe rank 56; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum48/100Medium-term price momentum. Underlying universe rank 53; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-128.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
5.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

PVLA shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 5.33, expected move of 12.4%, and Sharemaestro trend signal active.

Conviction45/100
Expected move12.4%
Put/call volume5.33
Pressure-59
Speculation11
Volatility86
Trend agreement38
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 64 relevant articles.

20 positive · 42 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move12.4%Nearest-chain priced movement where available.
52-week drawdown-13.8%Distance below the 52-week high.
13-week volatility10.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+57.6%Week of 27 Feb.
Worst week-12.2%Week of 24 Jul.
Latest week+0.7%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains7
Flat weeks0
Modest losses6
Sharp losses7
Recent vol10.1%13-week weekly-return volatility.
Base vol10.9%52-week weekly-return volatility.
Up/down split31/21Count of positive and negative weeks in the 52-week window.
Average skew8.4% / -4.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape73/100

Trend, activity pressure, participation, and risk combine to a 73/100 tape read.

 Indicator analysis69/100

Latest 12-week confirmation: trend 12/12, activity pressure 7/12, relative leadership 12/12.

Activity pressure 0.68; 7 reversal markers Next-Week ExpectancyPositive 58.04%

Next-week expectancy is positive with a 58.04% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50; Small Cap Core rank 56 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

PVLA shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 5.33, expected move of 12.4%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 12.4% Sentiment56/100

Weighted news tone is neutral across 64 relevant articles.

PVLA|Palvella Therapeutics Inc|Price:150.160|Chg%:+7.560 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026139.0 USD0.7%117.4 USD69.49 USD0.3729.55799.6KOn
24 Jul 2026138.0 USD-12.2%116.2 USD68.66 USD0.5131.501.4MOn
17 Jul 2026157.2 USD8.6%115.0 USD67.82 USD0.6549.941.2MOn
10 Jul 2026144.8 USD-1.4%113.1 USD66.73 USD0.2735.28961.2KOn
3 Jul 2026146.8 USD-1.0%111.5 USD65.77 USD0.0542.451.6MOn
26 Jun 2026148.2 USD31.0%110.0 USD64.76 USD-0.2648.302.2MOn
19 Jun 2026113.1 USD3.9%108.5 USD63.70 USD-0.6010.631.1MOn
12 Jun 2026108.8 USD0.1%107.9 USD63.07 USD-0.5110.991.7MOn
5 Jun 2026108.7 USD-8.3%107.0 USD62.47 USD-0.4115.081.6MOn
29 May 2026118.5 USD3.9%106.0 USD61.87 USD-0.1921.65510.6KOn
22 May 2026114.0 USD-0.2%104.7 USD61.11 USD0.0222.481.0MOn
15 May 2026114.2 USD-5.8%103.3 USD60.40 USD0.1726.341.1MOn
8 May 2026121.3 USD-4.4%102.0 USD59.66 USD0.3336.141.4MOn
1 May 2026126.8 USD2.6%100.3 USD58.80 USD0.3553.11967.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.